CD163 and breast cancer: In this study using real-world patient data, a high M2 (CD163+) TAM count represented a strong independent prognostic factor for an inferior outcome in HER2+ breast cancer; its prognostic value was evident across all the investigated survival endpoints and regardless of the administration of adjuvant trastuzumab and hormone receptor status.